ANDA 79046, held by Actavis Elizabeth. Oxymorphone Hydrochloride.
As of Nov 16, 2026, ANDA 79046 (Oxymorphone Hydrochloride), held by Actavis Elizabeth, was first approved by FDA on Jul 11, 2013, with 24 approved supplements and 0 published complete response letters.
| Jul 11, 2013 | Original application | Approved | None posted |
| Dec 13, 2010 | Original application | Approved |
| Oxymorphone Hydrochloride7.5MG · tablet, extended release;oral | Oxymorphone Hydrochloride | Discontinued |
| Oxymorphone Hydrochloride15MG · tablet, extended release;oral | Oxymorphone Hydrochloride | Discontinued |
| Oxymorphone Hydrochloride5MG · tablet, extended release;oral | Oxymorphone Hydrochloride | Discontinued |
| Oxymorphone Hydrochloride10MG · tablet, extended release;oral | Oxymorphone Hydrochloride | Discontinued |
| Oxymorphone Hydrochloride20MG · tablet, extended release;oral | Oxymorphone Hydrochloride | Discontinued |
| Oxymorphone Hydrochloride30MG · tablet, extended release;oral | Oxymorphone Hydrochloride | Discontinued |
| Oxymorphone Hydrochloride40MG · tablet, extended release;oral | Oxymorphone Hydrochloride | Discontinued |
| Jun 18, 2026 | Supplement 40REMS | Approved | None posted |
| Jan 5, 2026 | Supplement 39Labeling · Standard review | Approved | None posted |
| Nov 12, 2025 | Supplement 36Labeling · Standard review | Approved | None posted |
| Oct 31, 2024 | Supplement 37REMS | Approved | None posted |
| Dec 15, 2023 | Supplement 35Labeling · Standard review | Approved | None posted |
| Dec 15, 2023 | Supplement 34Labeling · Standard review | Approved | None posted |
| Dec 12, 2023 | Supplement 33Labeling · Standard review | Approved | None posted |
| Mar 4, 2021 | Supplement 32Labeling · Standard review | Approved | None posted |
| Oct 10, 2019 | Supplement 31Labeling · Standard review | Approved | None posted |
| Oct 10, 2019 | Supplement 30Labeling · Standard review | Approved | None posted |
| Sep 21, 2018 | Supplement 29Labeling · Standard review | Approved | None posted |
| Sep 18, 2018 | Supplement 28REMS | Approved | None posted |
| May 26, 2017 | Supplement 27REMS | Approved | None posted |
| Dec 16, 2016 | Supplement 26Labeling · Standard review | Approved | None posted |
| Dec 16, 2016 | Supplement 24Labeling · Standard review | Approved | None posted |
| Sep 30, 2016 | Supplement 25REMS | Approved | None posted |
| Apr 20, 2016 | Supplement 23REMS | Approved | None posted |
| Jun 26, 2015 | Supplement 21REMS | Approved | None posted |
| Nov 21, 2014 | Supplement 11Manufacturing | Approved | None posted |
| Aug 19, 2014 | Supplement 18REMS | Approved | None posted |
| Apr 17, 2014 | Supplement 16Manufacturing | Approved | None posted |
| Apr 16, 2014 | Supplement 13Labeling · Standard review | Approved | |
| Jul 11, 2013 | Original application | Approved | None posted |
| Apr 15, 2013 | Supplement 8REMS | Approved | None posted |
| Jul 9, 2012 | Supplement 4REMS | Approved | None posted |
| Dec 13, 2010 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters